Immunoassays for the incretin hormones GIP and GLP-1
- 1 August 2009
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 23 (4) , 425-432
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Non‐linear increase in GLP‐1 levels in response to DPP‐IV inhibition in healthy adult subjectsDiabetes, Obesity and Metabolism, 2008
- GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrationsAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat PancreasDiabetes Care, 1996
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.Journal of Clinical Investigation, 1991
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Hamster preproglucagon contains the sequence of glucagon and two related peptidesNature, 1983
- The incretin concept todayDiabetologia, 1979